The Impact of Residential Racial Segregation on Non-Small Cell Lung Cancer Treatment and Outcomes

被引:24
|
作者
Annesi, Chandler A.
Poulson, Michael R.
Mak, Kimberley S.
Tapan, Umit
Dechert, Tracey A.
Litle, Virginia R.
Suzuki, Kei
机构
[1] Boston Univ, Sch Med, Boston, MA 02118 USA
[2] Boston Univ, Med Ctr, Dept Surg, Boston, MA USA
[3] Boston Univ, Med Ctr, Dept Radiat Oncol, Boston, MA USA
[4] Boston Univ, Med Ctr, Dept Internal Med Hematol & Oncol, Boston, MA USA
[5] Boston Univ, Med Ctr, Div Acute Care & Trauma Surg Surg Crit Care, Dept Surg, Boston, MA USA
[6] Boston Univ, Med Ctr, Dept Surg, Div Thorac Surg, Boston, MA USA
来源
ANNALS OF THORACIC SURGERY | 2022年 / 113卷 / 04期
关键词
STAGE; RACE;
D O I
10.1016/j.athoracsur.2021.04.096
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Despite decreases in lung cancer incidence, racial disparities in diagnosis and treatment persist. Residential segregation and structural racism have effects on socioeconomic status for black people, affecting health care access. This study aims to determine the impact of residential segregation on racial disparities in non-small cell lung cancer (NSCLC) treatment and mortality. METHODS Patient data were obtained from Surveillance, Epidemiology, and End Results Program database for black and white patients diagnosed with NSCLC from 2004-2016 in the 100 most populous counties. Regression models were built to assess outcomes of interest: stage at diagnosis and surgical resection of disease. Predicted margins assessed impact of index of dissimilarity (IoD) on these disparities. Competing risk regressions for black and white patients in highest and lowest quartiles of IoD were used to assess cancer-specific mortality. RESULTS Our cohort had 193,369 white and 35,649 black patients. Black patients were more likely to be diagnosed at advanced stage than white patients, with increasing IoD. With increasing IoD, black patients were less likely to undergo surgical resection than white patients. Disparities were eliminated at low IoD. Black patients at high IoD had lower cancer-specific survival. CONCLUSIONS Black patients were more likely to present at advanced disease, were less likely to receive surgery for early stage disease, and had higher cancer-specific mortality at higher IoD. Our findings highlight the impact of structural racism and residential segregation on NSCLC outcomes. Solutions to these disparities must come from policy reforms to reverse residential segregation and deleterious socioeconomic effects of discriminatory policies. (c) 2022 by The Society of Thoracic Surgeons
引用
收藏
页码:1291 / 1298
页数:8
相关论文
共 50 条
  • [41] The treatment of advanced non-small cell lung cancer
    Spiro, SG
    Silvestri, GA
    CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (04) : 287 - 291
  • [42] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [43] Afatinib for the treatment of non-small cell lung cancer
    Biello, Federica
    Maggioni, Claudia
    Rijavec, Erika
    Genova, Carlo
    Barletta, Giulia
    Gualco, Elisa
    Truini, Anna
    Coco, Simona
    Dal Bello, Maria Giovanna
    Vanni, Irene
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1357 - 1364
  • [44] Personalized treatment in non-small cell lung cancer
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2012, 64 (04): : 377 - 386
  • [45] Aptamers in Non-Small Cell Lung Cancer Treatment
    Wieleba, Irena
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    MOLECULES, 2020, 25 (14):
  • [46] Targeted treatment of non-small cell lung cancer
    Scheffler, Matthias
    Michels, Sebastian
    Nogova, Lucia
    INNERE MEDIZIN, 2022, 63 (07): : 700 - 708
  • [47] Current treatment of non-small cell lung cancer
    Tonato, M
    TUMORI JOURNAL, 2002, : S7 - S8
  • [48] Pembrolizumab for the treatment of non-small cell lung cancer
    Lim, Sung Hee
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (03) : 397 - 406
  • [49] Pemetrexed in the treatment of non-small cell lung cancer
    Shepherd, FA
    SEMINARS IN ONCOLOGY, 2002, 29 (06) : 43 - 48
  • [50] Sintilimab for the treatment of non-small cell lung cancer
    Zhang, Lin
    Lin, Weihao
    Tan, Fengwei
    Li, Ning
    Xue, Qi
    Gao, Shugeng
    Gao, Yibo
    He, Jie
    BIOMARKER RESEARCH, 2022, 10 (01)